Erschienen in:
02.02.2019 | Editorial
MRI-targeted biopsies: What’s next?
verfasst von:
Guillaume Ploussard, Alberto Briganti
Erschienen in:
World Journal of Urology
|
Ausgabe 2/2019
Einloggen, um Zugang zu erhalten
Excerpt
The two last years have witnessed the confirmed advent of MRI and MRI-targeted biopsies in routine prostate cancer management thanks to the publication of a high level of evidence trials. MRI does better than TRUS biopsies in ruling out clinically significant disease (PROMIS trial), and MRI followed by targeted biopsies alone improves its detection (PRECISION trial) as compared with systematic biopsies [
1,
2]. The question is no longer whether we should use MRI before biopsy and target the lesion if positive, but how this new information that implements our reflection on daily practice influences our treatment decision-making process. …